A brief history and summary of studies designed to elucidate the role of monoamine oxidase (MAO) in schizophrenia are presented. The majority of these studies have reported a decrease in the platelet enzyme activity of chronic schizophrenic patients when compared to controls. Difficulties encountered when comparing MAO activity measured in different patient populations are also considered. Finally, the significance of decreased platelet MAO activity is discussed with respect to its possible etiological role in some forms of schizophrenia.
We began our examination of monoamine oxidase (MAO) in schizophrenic patients in an attempt to understand another phenomenon. We had noted (Wyatt, Saavedra, and Axelrod 1973b) that an enzyme (a nonspecific methyltransferase) in the platelet, which seemed capable of forming the hallucinogen dimethyltryptamine (DMT) from tryptamine (Wyatt, Saavedra, and Axelrod 1973b) , was more active in schizophrenic patients than in controls. We knew of few clinical situations in which an enzyme was more active in a disease state; usually, the activity is decreased. One reason for this apparent increase in activity, we thought, might be a decrease in another enzyme involved in tryptamine metabolism. The other important enzyme was, of course, MAO, and Dr. Murphy had already demonstrated a decrease in its activity in some patients with affective disorders (Murphy and Weiss 1972) .
As we began to notice that schizophrenic patients' platelet MAO activity as a group was lower than that in controls, we recalled that Birkhauser (1940) had seen the same phenomenon in autopsied brains of schizophrenics [a number of subsequent studies have
; not confirmed Birkhauser's original finding]. Since Birkhauser's early work and our own first report of reduced platelet MAO activity in schizophrenic patients , a large body of investigative work in this area has developed.
In June 1979, we reviewed 31 published studies on chronic schizophrenic patients (table 1) , beginning with our own first article on platelet MAO activity . All but 6 found a decrease in MAO activity, and in 22 studies, the decrease was statistically significant. The chance of 26 of 32 studies demonstrating a decrease is 1 in 4,500 (sign test), and the possibility of 22 of the 32 studies indicating significantly lower MAO in schizophrenics than controls at the .05 level is less than 1 in 10 21 (binomial test). We believe that these probabilities indicate that MAO activity is decreased in some chronic schizophrenic patients nostic standardization (such as the definition of acute, remitting, and chronic). Tables 1 and 2 indicate that while the chronic form of the disorder generally is associated with decreased MAO activity, less severe forms usually are not.
Choosing the proper control group is important since it is now recognized that many people who do not have a psychiatric diagnosis have low platelet MAO activity (Berger et al. 1978; Buchsbaum, Coursey, and Murphy 1976; . Matching the age and sex of the subjects also is important (Robinson et al. 1971) . While the blood samples from patients who are being given drugs known to inhibit MAO activity clearly will confound the results of the standard assays, platelet MAO of patients on stable dosages of neuroleptics is not affected .
With the exception of one study that indicates that acute glucose doses can markedly decrease platelet MAO activity (Demisch, Demisch, and Seiler 1979) , no other data are available to indicate that the diet of reasonably well-nourished patients alters platelet MAO activity (Murphy et al. 1977a ).
However, hormonal status is probably important; platelet MAO activity in the adult human female varies in a cyclic fashion, being highest just before ovulation and lowest in the postovulatory period (Belmaker et al. 1974) .
As discussed elsewhere in this issue of the Bulletin, the assay procedure is extremely important in making an accurate and reliable determination of platelet MAO activity. (The intraclass correlation in our laboratory for split samples assayed the same day is .99, and .94 for samples assayed on different days.) The intraclass correlation for platelet samples obtained at different time points is .92 for controls and .79 for patients (Wise et al. 1980 ; this issue). The reasons for this greater biological variability in the schizophrenic patients are unknown.
Delineation of Subgroups by Symptoms
In addition to the course of illness (chronic vs. acute) dimension, three types of symptom complex have been related to platelet MAO activity: schizoaffective, hallucinating, and paranoid. The first subgroup is characterized by affective symptoms; patients are variously described as having schizophrenia-related depression, anergic depression, and schizoaffective schizophrenia (see table 3 ). There may be a trend for these patients to have elevated platelet MAO activity. Schildkraut et al. (1976) , Becker and Shaskan (1977) , Orsulak et al. (1978), and Meltzer et al. (1980; this issue) found the presence of auditory hallucinations to be useful in discriminating schizophrenic patients with decreased platelet MAO activity.
Our laboratory has found the presence of paranoia and paranoid features to discriminate chronic schizophrenic patients with decreased platelet MAO activity. In acute schizophrenic patients we found that patients with paranoid and grandiose delusions tended to have low MAO activity (Carpenter, Murphy, and Wyatt 1975) . This observation was confirmed in both a retrospective ) and a prospective ) study of chronic patients. Additionally, other groups have also found this relationship (Demisch et al. 1977; Sullivan et al. 1978b) . Landowski and Afeltowicz (1977) , studying a group of 34 paranoid schizophrenics, found lowest platelet MAO in those males with the most paranoid symptoms (r = -.71). However, they did not find any correlation in a smaller group of female schizophrenics or an association of low platelet MAO with the presence of auditory hallucinations as suggested by Schildkraut et al. (1976) . Nonetheless, within the male group, there appears to be a suggestion of an association of low platelet MAO and the intensity of hallucinations (Landowski and Afeltowicz 1977; their figure 2). Bond, Cundall, and Falloon (1979) found that four hallucinating acute admission schizophrenics had lower platelet MAO activity than 11 nonhallucinating controls, while Bond, Cundall, and Falloon (1979) reported that 37 percent of the patients were hallucinating compared to 87 percent for the Mann and Thomas (1979) study.
The Biological Significance of the Decrease in Enzyme Activity
There are a number of preliminary lines of evidence indicating that when MAO is decreased in activity, either the enzyme or its biochemical environment may be physically altered. Several investigators have reported a difference in substrate specificity of the platelet enzyme of schizophrenics (Demisch et al. 1977; Meltzer and Stahl 1974; Zeller et al. 1975) . Using a variety of substrates, others have found differences in the Michaelis constant (Km) (Belmaker, Reches, and Ebstein 1977b; Berrettini, Vogel, and Clouse 1977; Geller et al., personal communication) . Recently, lower K m 's with tyramine as a substrate have been reported in chronic schizophrenics, particularly those with paranoid symptoms (Kobes et al. 1979) . Landowski (1977) also found the K m to be lower in predominantly paranoid schizophrenics than in normal controls with benzylamine as substrate. While platelet MAO activity in patients and controls is at least in part under genetic control , low platelet MAO activity is not unique to chronic schizophrenic patients (Buchsbaum, Coursey, and Murphy 1976; . Furthermore, inhibiting MAO with MAO inhibitors generally does not produce a psychosis, and brain MAO is not generally decreased when it has been examined in autopsied material .
Finally, in most genetic disorders in which an enzyme deficit has been shown to be causative of the disorder, the enzyme activity itself is almost undetectable. No study of platelet MAO activity in schizophrenic patients has reported a mean reduction greater than 68 percent from normal control subjects (Meltzer and Stahl 1974) . The significance of the relatively mild decrease in MAO activity is unclear. Nevertheless, one indication that low platelet MAO activity may reflect similar systemic alterations is the high inverse correlation found by Sullivan et al. (1980) between platelet MAO activity and urinary tryptamine concentration.
Some indirect evidence of an association between platelet MAO activity and biogenic amines in the central nervous system does exist. Kleinman et al. (1979) found a statistically significant correlation between plasma prolactin, which is under inhibitory control by tuberoinfundibular dopamine, and platelet MAO activity in chronic drug-free schizophrenic patients and normal subjects with low platelet MAO activity. This report suggests that platelet MAO activity reflects pituitary hypothalamic dopamine activity.
Eye blink rates, which appear to be related to central dopaminergic activity, are decreased in low dopaminergic states such as Parkinson's disease, while high rates are seen in dopaminergic excess states such as tardive dyskinesia (Cegalis and Sweeney 1979; Stevens 1978) . In a group of drug-free chronic schizo-, phrenic patients, a significant inverse correlation between platelet MAO activity and the rate of eye blinking has been determined (W. Freed et al., unpublished data) . This finding is consistent with a relationship between platelet MAO activity and the central nervous system's dopaminergic activity.
Cause or Association?
Although there is indirect evidence for platelet MAO activity being reflective of central MAO activity, a decrease in brain MAO activity is not essential for MAO to be causally important in schizophrenia. Presuming that peripheral tissues other than the platelet and white cells are involved, but not the brain, can the decrease in MAO activity in those tissues be causative? We believe that it could be, but there is no evidence thus far that it is. An example of how this might take place is readily at hand. Phenylketonuria, a disorder whose principal symptoms and signs are derived from altered brain function, is not primarily a brain disorder, but one of the liver. The enzyme phenylalanine hydroxylase, which converts phenylalanine to tyrosine, is deficient in the liver (little or none is normally present in the brain), and abnormally high metabolites cross from the blood into the brain, disrupting normal function.
A similar phenomenon could occur in schizophrenia. For example, of the known endogenous substrates for platelet MAO, phenylethylamine (PEA) has the greatest affinity for the enzyme. PEA is structurally similar to amphetamine (a-methyl-PEA) and produces many analogous behavioral phenomena in animals (Borison, Havdala, and Diamond 1977; Moja et al. 1977) . PEA readily crosses the blood-brain barrier. If PEA were elevated in schizophrenia, it might be expected to produce a psychosis similar to that produced by amphetamine. Of the five studies of urinary PEA in schizophrenic patients (Schweitzer, Friedhoff, and Schwartz 1975; Suzuki and Yagi 1977) , three (Fischer et al. 1968 (Fischer et al. ,1972 suggest that PEA might be elevated in the urine of schizophrenic patients.
Simply having decreased MAO activity does not appear to be enough to produce disease. Perhaps another genetic imbalance or environmental factors are needed to precipitate the onset of schizophrenia. There is a body of literature, for example, suggesting that a higher proportion of schizophrenic patients are heterozygous for phenylketonuria than would be expected in the general population ). Could two genetic abnormalities (having low MAO and being a heterozygote for phenylketonuria) that are relatively innocuous when found by themselves produce a major disorder when they are found together in the same person? Alternatively, ameliorative factors may be present in most people but missing in others.
Summary
Our review of the data indicates that low platelet MAO activity is associated with some forms of schizophrenia, probably the more chronic ones and those where there is either paranoia or hallucinations. The relationship of this finding to the etiology of schizophrenia is unclear, but data are accumulating that the finding has some physiological significance.
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